MDTMDT AGM: Directors, Auditor & Share Issuance
Medtronic (MDT) shareholders elected directors, approved the auditor and authorized share issuance at the 2026 AGM. Key governance and capital implications.
Medtronic plc
MDTMedtronic Completes MiniMed Separation (MDT)
Medtronic (MDT) finalizes MiniMed Group, Inc. separation on 2026-10-19; relates to Diabetes unit, following Dec 2025 restructuring and $16M Q3 FY2026 charge.
Medtronic plc
MDTMedtronic Names President for Greater China
Medtronic (MDT) appoints Michael Marinaro as President overseeing Greater China on Oct 19, 2026. Key investor implications for international revenue and strategy.
Medtronic plc
MDTMedtronic Buyback Approved — MDT Repurchase
Medtronic shareholders approve overseas share repurchase, enabling part of the $5.0B buyback authorization; implications for capital allocation and leverage.
Medtronic plc
MDTMedtronic Launches MiniMed Exchange Offer
Medtronic (MDT) begins MiniMed share exchange and corrects the offer's tender deadline as part of its planned Diabetes separation.
Medtronic plc
MDTMedtronic Completes CathWorks & Anteris Deals
Medtronic (MDT) completes two cardiovascular acquisitions — CathWorks and Anteris — in Q3 FY26. Strategic move to expand Cardiovascular portfolio; key financial context included.
Medtronic plc
MDTMDT: Medtronic Gains Key Regulatory Approvals
Medtronic (MDT) secures CE Mark and FDA clearances in Q3 FY26, a regulatory step supporting product launches across device portfolios.
Medtronic plc
MDTMedtronic Issues $419M in New Shares — MDT
Medtronic (MDT) raised $419M via new share issuance in the nine months to Jan 23, 2026. Context on capital allocation, repurchase plans and balance-sheet risks.
Medtronic plc
MDTMedtronic Q3 Report: Growth, Guidance Upheld
MDT Q3: strong revenue, FDA approvals, CathWorks M&A progress, MiniMed separation underway; company upholds full-year guidance.
Medtronic plc
MDTMedtronic Reports Strategic Growth Shift (Q3 FY26)
MDT Q3 FY26: revenue rose 8.7% driven by Cardiovascular strength and acquisitions. MiniMed separation, CathWorks option, $5B buyback and legal/tax risks noted.
Medtronic plc
MDTMDT: No New Divestitures; Legacy Impacts Persist
Medtronic (MDT) reports prior exits continue to affect results; no new divestitures announced. Segment revenue, MiniMed separation, legal and tax risks detailed.
Medtronic plc
MDTMDT: No New Divestitures Reported This Quarter
Medtronic (MDT) 8-K: no new divestitures this quarter. 8-K outlines impacts from prior sales and relates to portfolio moves including MiniMed separation.
Medtronic plc
MDTMDT Q3 FY26: Revenue Up 8.7%, EPS Mixed
Medtronic (MDT) Q3 FY26: revenue rose 8.7% while GAAP and non‑GAAP EPS diverged. Segment, geographic breakdown and risks for investors (Feb 17, 2026).
Medtronic plc
MDTMedtronic Issues $419M in New Shares (MDT)
Medtronic (MDT) issued $419M in new shares in the nine months to Jan 2026. Summary, context and investor implications for capital allocation and risk.
Medtronic plc
MDTMDT: EVP Gregory L. Smith to Retire in Dec 2025
Medtronic (MDT) EVP Gregory L. Smith will retire in Dec 2025; company to accelerate vesting of outstanding equity awards. Investor implications and context.
Medtronic plc
MDTMedtronic Re-elects 12 Board Directors (MDT)
Medtronic (MDT) re-elected 12 directors at its 2025 AGM. Board continuity preserves oversight of MiniMed separation, M&A, capital allocation and risks.
Medtronic plc
MDTMedtronic Updates Shareholder Rights - MDT
Medtronic amends its Articles to revise voting and share issuance rules. Key implications for governance, dilution risk and capital allocation for investors.
Medtronic plc
MDTMedtronic Refinances Senior Notes, Issues €1.5B
Medtronic (MDT) repays €500M notes and issues €1.5B in new senior debt as part of its debt-management and capital allocation strategy.
Medtronic plc
MDTMedtronic Issues €1.5B Senior Notes
Medtronic (MDT) issues €1.5B in senior notes on Sept 16, 2025 and uses proceeds to redeem €500M of outstanding debt; impact on capital structure and investor risks.
Medtronic plc